OBJECTIVE: To study the clinical results of hepatic radioembolization with Yttrium-90 (90Y) glass microspheres in the treatment of primary @entity96 . METHODS: Seventeen @entity1 with @entity96 were treated with glass microspheres from August 1996 to May 1998. Hepatic radioembolization with 90Y and lipiodol-ultrafluid was used. Percutaneous port-catheter system (PCS) implantations via femoral artery were performed in 12 @entity1 . RESULTS: In the 17 @entity1 , their mean ratio of absorbed doses between @entity5 and normal liver was 2.4:1. CT showed a significant reduction in @entity5 size in 11 of the 17 @entity1 . Average survival was 19.5 months. The indwelling catheters of all the 12 @entity1 were patent and no catheter tip locations were found. CONCLUSIONS: 90Y glass microsphere is one of the @entity3987 . Not only good responses to the therapy of 90Y glass microspheres can be achieved in @entity1 with metastatic @entity96 , but also in those with primary @entity96 , specially the localized or hypervascular mass. The @entity1 with massive arterioportal shunt should not be limited to this form of radiation therapy. The percutaneous PCS implantation via the femoral artery is a new passageway for the treatment of primary @entity96 with 90Y glass microspheres and other interventional therapy.

Hepatic radioembolization with Yttrium-90 glass microspheres for treatment of primary XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity3987 :: ('MESH:D057826', 'Disease') :: ['best radioisotopes'] @entity96 :: ('MESH:D008113', 'Disease') :: ['liver cancer']
@entity96 :: (MESH:D008113,Disease) :: ['liver cancer']
